“This event was fantastic, and it was an honor to be a presenter,” says Dr. Maurice Khosh.

NEW YORK (PRWEB)
May 12, 2023

Well-respected NYC facial plastic surgeon, Dr. Maurice Khosh was a recent lecturer on the topic of non-surgical rhinoplasty at the Minimally Invasive ENT/Open Forum in Saratoga, Florida, in April 2023. At the conference, Dr. Khosh discussed the most recent updates on available non-surgical options for rhinoplasty including liquid rhinoplasty (filler injections) and Botox or other neurotoxin treatments. He described the state-of-the-art techniques for nasal enhancement and reviewed the pearls and pitfalls of the treatments with the surgeons in the audience. Dr. Khosh is a true leader in the world of aesthetic surgery and has excellent credentials and a superior level of training. As a double board-certified facial plastic surgeon, his education and experience allow him to perform facial enhancements that are exceptionally balanced and natural in appearance. Dr. Khosh is also widely recognized for his specialization in treating breathing issues during rhinoplasty and delivers a wide range of reconstructive procedures to address functional, trauma or cancer-related defects of the face, nose and scalp. Beyond plastic surgery procedures, he also offers a full menu of non-invasive services, including rejuvenation treatments for the eyes, cheeks, lips and neck.

“This event was fantastic, and it was an honor to be a presenter,” says Dr. Maurice Khosh.

More about Dr. Maurice M. Khosh:

Widely known as one of the top professionals in his field, Dr. Maurice Khosh obtained his graduate medical training at Albert Einstein College of Medicine in New York and completed his residency training at Columbia University. He then pursued a fellowship in facial plastic surgery at the University of Washington in Seattle. Dr. Khosh returned to New York where he joined the faculty at Columbia Presbyterian Medical Center as the director of Facial Plastic Surgery Clinics, prior to moving into private practice. He is a fellow of the American College of Surgeons, member of the American Academy of Facial Plastic and Reconstructive Surgery and the American Academy of Otolaryngology-Head and Neck Surgery. As a perennial recipient of Castle Connolly Top Doctors list and Best Doctors in America list, Dr. Khosh is a highly sought-after facial plastic surgeon due to patient-centered focus, unsurpassed surgical skill and vast clinical experience. For more information on the services offered by Dr. Maurice Khosh, please visit http://www.facedoctornyc.com, or contact his office located at 580 Park Avenue in Manhattan at (212) 339-9988.

Share article on social media or email:

Men Having Babies Returns to Chicago on June 2-3, 2023

Illinois was the first U.S. state to make surrogacy considerably more affordable for same-sex couples and singles with its amendment to the state’s definition of ‘infertility,’ which resulted in inclusion of same-sex couples in insurance coverage for a part of the process.

CHICAGO (PRWEB)
May 12, 2023

Known for its unbiased, comprehensive conferences for gay men, the international nonprofit organization Men Having Babies (MHB) returns to Chicago in cooperation with Center on Halsted, along with 19 reputable gay-friendly agencies, clinics, law firms, and other surrogacy providers from the Midwest and beyond.

This year, MHB has made large changes to the itinerary in order to accommodate the needs and interests of gay men who attend the conference, arriving from the whole Midwest area. The new session ‘Social Attitudes Towards Surrogacy’ was added to provide a larger view on ethical surrogacy, and to discuss some of the major misconceptions held by surrogacy opponents, who often use those to attack the gay community.

Also new, the ‘Surrogacy Costs’ session addresses the biggest concern for gay men, who are often overwhelmed by the financial burden that is involved with having a biological child.

Other new and improved sessions including the panel on Egg Donation, and Foundations for a Successful Journey, while the highly popular ‘Personal Stories Panel’ was expanded to include perspectives of fathers through surrogacy, as well as children born via surrogacy, surrogates and egg donors.

Illinois was the first U.S. state to make surrogacy considerably more affordable for same-sex couples and singles with its amendment to the state’s definition of ‘infertility,’ which resulted in inclusion of same-sex couples in insurance coverage for a part of the process. The conference will discuss how to use this benefit, as well as workplace benefits, financial assistance programs and more.

Steven Snyder from IARC Surrogacy, MHB Advisory Board Member and Chicago conference Platinum Sponsor, said: “As a former high school teacher, I fully understand the value of education. The overwhelming strength of both IARC and Men having Babies is focusing primarily on the critical information and education necessary for a successful third-party reproduction process.”

Proceeds from the conference’s sponsorship fees benefit MHB’s Gay Parenting Assistance Program (GPAP), which provides prospective parents with over a million dollars’ worth of cash grants, discounts and free services on an annual basis, from over 130 leading service providers.

Dr. Shamma from IVF Michigan & Ohio, MHB Advisory Board Member and Platinum Sponsor said: “Education and support are the crucial first steps on this exciting journey to becoming a parent. Men Having Babies’ conferences offer all of that and more.”

The majority of the 19 exhibitors at the MHB Midwest conference are supporters of GPAP, as well as the organization’s Membership Benefits Program, including Platinum sponsors IARC Surrogacy and IVF Michigan & Ohio, and additional conference sponsors: Circle Surrogacy, Kindbody, San Diego Fertility Center, Same Love Surrogacy, Fertility Specialists of Texas, Family Source Consultants, Golden Surrogacy, Fertility Centers of Illinois, Worldwide Surrogacy Specialists, Daylight Grow, Law Office of Ryan C. Ferrante, Art Risk Financial & Insurance Solutions, Gift of Life Surrogacy, Ross & Zuckerman LLP, Family Choice Surrogacy, Desai & Miller, and EMD Serono.

Registration for the Midwest Men Having Babies Surrogacy Conference & Gay Parenting Expo and more information is now available at menhavingbabies.org/chicago.

Full event information:

Men Having Babies 2023 Midwest Surrogacy Conference & Expo at the Center on Halsted (3656 North Halsted, Chicago)

June 2, 2023 5:00 PM – 8:00 PM and June 3, 2023, 9:00 AM- 8:00 PM

Registration: menhavingbabies.org/chicago

Share article on social media or email:

Any early warning system benefits from including genomics in combination with other data streams.

NEW YORK (PRWEB)
May 12, 2023

Biotia, a health tech company based in New York City, announced today its launch of the GeoSeeq Watchtower System. Using genomics, the program provides support for 12 groups monitoring infectious disease hotspots to profile emerging infectious disease risks.

The COVID-19 pandemic highlighted the fragility of global health, social systems and economies and revealed the need for a more robust global infectious disease-monitoring system. With support from The Rockefeller Foundation, the GeoSeeq Watchtower System is generating data to be shared publicly and onboarded onto the GeoSeeq platform, which will serve as an early warning system for the world, allowing health professionals to identify and track emerging infectious diseases in real time and help prevent pandemics.

The GeoSeeq Watchtower System was announced at a recent presentation to the United Nations General Assembly. At that presentation, Dr. Niamh O’Hara, CEO and cofounder of Biotia, outlined that “any early warning system benefits from including genomics in combination with other data streams.” She went on to add that “climate data is especially important because we see changes in climate driving much of the increases in infectious disease risk, especially for vector-borne pathogens.”

The GeoSeeq platform will use data from many sources, including climate forecasts, land- and water-use records, mobility and travel predictions, social determinants of health and epidemiological and microbial genomics. It will leverage the latest advancements in computational technology, access to growing numbers of digital data resources and an increasing pool of global talent to predict, simulate and optimize outbreak response.

An esteemed group of scientists — affiliated with the MetaSUB consortium founded by Dr. Chris Mason of Biotia and Weill Cornell Medicine — was selected to join the program, including the following: Anne Wyllie, Ph.D., Yale School of Public Health; Olayinka Osuolale, Ph.D., Elizade University; Sion Williams, Ph.D., University of Miami; Gregorio Iraola, Ph.D., Kinzbio; Josefina Gutiérrez, DVM, Austral University of Chile; Xavier Rodo, Ph.D., Barcelona Institute for Global Health (ISGlobal); Sofya Pozdniakova, Ph.D., ISGlobal; Tieliu Shi, Ph.D., East China Normal University; Rafael Freitas, Ph.D., Fiocruz; Gabriel da Luz Wallau, Fiocruz; Soojin Jang, Ph.D., Institut Pasteur Korea; and Erik Andersson, University of Illinois Chicago.

The GeoSeeq Watchtower System is already making significant strides: It is currently running a viral surveillance program at avian migratory hotspots in Chile (led by Dr. Gutiérrez), tracking coinfection of malaria and viruses in patients in a rural community in Nigeria (led by Dr. Osuolale) and monitoring circulating viruses using mosquito metagenomics in Brazil (led by Dr. Freitas).

“Creating this early-warning system for infectious diseases is the goal of our scientific collaboration,” Dr. Freitas said. “We have learned from the past, and an early-warning system like this would have been instrumental in managing the outbreak of the Zika virus outbreak in Brazil in 2015.”

The group is partnering with public health professionals to build dashboards that will help the GeoSeeq Watchtower System positively impact local health. For example, this will help guide local professionals on when and where they should spray for mosquitoes and mobilize resources to specific regions based on risk levels.

“The vision for the early-warning system is to empower local researchers and support the development of community-driven projects and models,” said Dr. David Danko, CTO of Biotia. “In this way, we are democratizing data and access to AI tools and insights.”

Learn more about the impact of GeoSeeq’s early-warning system for infectious diseases and watch highlights from Biotia’s presentation to the United Nations in this video. For more information, visit GeoSeeq.com.

About Biotia

Biotia is a health-tech company located in New York, N.Y., that leverages sequencing-based technology and proprietary AI-powered software to rapidly and accurately identify microorganisms and antimicrobial resistance. Its mission is to fight infectious diseases by deploying the leading reference library of microbes worldwide. As a spinout company of Jacobs Technion-Cornell Institute at Cornell Tech, Biotia has a New York State CLIA lab for infectious disease diagnostics testing affiliated with SUNY Downstate Health Sciences University. Connect on Twitter, Facebook and LinkedIn.

Share article on social media or email:

Frontline Healing Foundation is honored to be a Carry The Load non-profit partner for their 2023 Memorial May events to restore the true meaning of Memorial Day – for the sixth year.

We’re grateful to Carry The Load for providing our warrior community, and people all over the world with a meaningful way to honor and remember those who sacrifice for our freedom by putting their lives on the line every day. – Jordyn Jureczki, Frontline Healing Foundation CEO

SAN ANTONIO, Texas (PRWEB)
May 12, 2023

Frontline Healing Foundation is proud to announce it will be a Carry The Load non-profit partner for the 2023 Memorial May campaign. Carry The Load is a non-profit that provides active ways to connect Americans to the sacrifices of our military, veterans, first responders, and their families. Together, they kicked off Memorial May on Thursday, April 27, 2023, to raise awareness for the true meaning of Memorial Day. Join us as we unite with Carry The Load this year at San Antonio, Texas.

Frontline Healing Foundation CEO Jordyn Jureczki expressed thanks; “We’re grateful to Carry The Load for providing our warrior community, and people all over the world with a meaningful way to honor and remember those who sacrifice for our freedom by putting their lives on the line every day.”

Supporters are encouraged to join Frontline Healing Foundation’s team at https://frontlinehealingfoundation.org/carrytheload to raise funds and participate throughout the month of May. One hundred percent of funds raised through Frontline Healing Foundation’s team page now through Memorial Day will go directly back to the Frontline Healing Foundation.

“The funds we raise this year will continue to go towards funding hardships for addiction and PTSD treatment programs for warriors (active military, veterans and first responders) struggling, ” says Jordyn Jureczki, Frontline Healing Foundation CEO.

How to get involved:

• People of all ages can walk with the National Relay team or attend a Rally at a location near them. Registration is complimentary at carrytheload.org/Memorial-May.
• Join the Dallas Memorial March.
• Host a Carry it Anywhere event on your own.
• Educate youth with Carry The Flag activities that help inspire patriotism.

“Honoring our nation’s heroes is a unifying effort where people come together as a country and pay tribute to the sacrifices made for our freedom,” says Stephen Holley, co-founder, president and CEO of Carry The Load and veteran U.S. Navy SEAL. “It’s truly inspiring to see the positive impact these partnerships have on the lives of so many people around the world.”

ABOUT Frontline Healing Foundation (Bandera, Texas)

The Frontline Healing Foundation is a 501(c)(3) that accepts donations to help heal our protectors with their peers. One of the missions of the foundation is to provide financial aid through hardship grants that assist in covering the cost of treatment at Warriors Heart and at other programs to help our military, veterans and first responders get the treatment they have earned and deserve. It is a separate entity from the Warriors Heart treatment facility. https://www.frontlinehealingfoundation.org

Follow our news on social media here:

Facebook

https://www.facebook.com/frontlinehealingfoundation

Instagram @frontlinehealingfoundation

https://www.instagram.com/frontlinehealingfoundation

Join the Frontline Healing Foundation Team – Carry the Load – Memorial May Campaign 2023 here:

https://frontlinehealingfoundation.org/carrytheload

MEDIA CONTACT

Liz Kelly

PR for Frontline Healing Foundation

310-987-7207

ABOUT CARRY THE LOAD

Carry The Load is a 501(c)3 nonprofit founded in 2011 by veteran U.S. Navy SEALs Clint Bruce and Stephen Holley. Carry The Load’s mission is to provide active ways to connect Americans to the sacrifices made by our military, veterans, first responders, and their families. It focuses on three outreach programs: Awareness, Continuum of Care, and Education. For more, visit http://www.carrytheload.org or http://www.carrytheload.org/media-resources.

Share article on social media or email:

Crossroads Eye Care Associates

“I couldn’t be more excited to be joining the prestigious OCLI Vision team. The team is renowned for their innovations and comprehensive approach to care. We’re looking forward to stronger partnership with our esteemed colleagues and providing even better care to our patients.” noted Dr. D’Orazio.

MCMURRAY, Pa. (PRWEB)
May 11, 2023

Spectrum Vision Partners are thrilled to announce the acquisition of Crossroads Eye Care Associates to continue to build the AIO|OCLI Vision presence in Pittsburgh. Crossroads Eye Care Associates is dedicated to helping their patients achieve the best ocular health through the diagnosis and treatment of various eye conditions and cataract, glaucoma, retina, and eyelid surgeries. With the acquisition of Crossroads, Spectrum Vision Partners now operates 15 eye care clinics and two surgery centers in the state.

OCLI Vision is a leading ophthalmology practice whose growth is supported by the management and administrative services of Spectrum Vision Partners (SVP), an organization serving many of the top ophthalmologists, optometrists and ambulatory eye surgery centers in New York, New Jersey, Connecticut, Pennsylvania, and West Virginia. Crossroads Eye Care Associates is Spectrum’s 9th acquired location so far this year.

“It is with great excitement that I welcome the team from Crossroads Eye Care Associates to the OCLI Vision team! We love expanding our team of talented eye care providers,” noted Tom Burke, SVP’s CEO. “With the addition of Dr. Thomas D’Orazio, an experienced ophthalmologist, and Dr. Rebecca Knorr-Peters, a comprehensive optometrist, we’re able to provide more communities in PA access to top-tier, innovative eye care services. With each new acquisition, we enhance our ability to meet our patients’ unique needs.”

“We are thrilled to welcome Drs. D’Orazio and Knorr-Peters to our practice,” states Lisa Cibik, MD, AIO|OCLI Vision’s Laser Cataract Surgeon and Comprehensive Ophthalmologist. “And look forward to collaborating together on the eye care of more patients in the region”.

The Crossroads office is located at 4160 Washington Rd., McMurray, PA. Dr. Thomas J. D’Orazio has been serving the community for over a decade, specializing in comprehensive ophthalmic care including advanced cataract surgery, glaucoma treatment and management, diabetic eye care and macular degeneration management and cosmetic Botox.

“I couldn’t be more excited to be joining the prestigious OCLI Vision team. The team is renowned for their innovations and comprehensive approach to care. We’re looking forward to stronger partnership with our esteemed colleagues and providing even better care to our patients.” noted Dr. D’Orazio.

For questions or further information regarding the OCLI Vision team or Spectrum Vision Partners, please contact:

Tom Burke

Chief Executive Officer

tburke@spectrumvisionpartners.com

Greg Wappett

Chief Development Officer

gwappett@spectrumvisionpartners.com

About OCLI Vision

Founded in 1997, OCLI Vision (http://www.ocli.net) is one of the leading ophthalmology practices in the United States. The practices of OCLI Vision offer eye care services at locations throughout Connecticut, New Jersey, New York, Pennsylvania and West Virginia. OCLI Vision is led by a large group of highly skilled ophthalmologists and optometrists in each major sub-specialty of eye care who provide comprehensive eye care services, including treatment for cataracts, corneal disease, glaucoma, retinal disease, oculoplastics, refractive surgery, and neuro-ophthalmology.

About Spectrum Vision Partners

Spectrum Vision Partners (SVP) (http://www.spectrumvisionpartners.com) is a leading management services organization, serving the ophthalmology sector. With over 1,400 employees providing world-class practice management and administrative solutions to a network of nationally renowned, multi-specialty ophthalmologists in New York, New Jersey, Connecticut, Pennsylvania and West Virginia, SVP supports over 50 clinic locations, five state-licensed ambulatory surgery centers, and over 150 surgeons, doctors and other medical professionals. SVP provides a comprehensive set of business support functions, including billing and collections, credential services, marketing, physician recruitment, ASC development, financial and accounting services, benefits and payroll management and information technology. The company’s corporate service center is located at 825 East Gate Boulevard, Suite 111, Garden City, NY 11530.

About Blue Sea Capital

Blue Sea Capital (http://www.blueseacapital.com) is a private equity firm based in West Palm Beach, Florida, that invests in growth-oriented lower middle market companies with EBITDA of up to $30 million. The firm has over $1.3 billion in committed capital and invests across three industry verticals: aerospace & defense, healthcare and industrial growth. Blue Sea Capital’s strategy is to partner with talented leaders and differentiated companies, typically as the first or second institutional investor, and deliver strategic and operational value-add that drives growth acceleration, industry outperformance and business transformation.

Share article on social media or email:

SITC is proud to continue to bring together the best and brightest minds in cancer immunotherapy to further the science and educate the next generation of scientists and clinicians.

MILWAUKEE (PRWEB)
May 11, 2023

The Society for Immunotherapy of Cancer (SITC) is excited to announce Susan Kaech, PhD, from Salk Institute as the Keynote Speaker at its 38th Annual Meeting and Pre-Conference Programs. The title of her presentation is “Stressing Out the Immune System in Cancer.” SITC is also hosting Robert D. Schreiber, PhD, FAIO, Washington School of Medicine, the 2023 recipient of the Richard V. Smalley Memorial Award and Lectureship, the society’s most prestigious award and which honors those who have been pioneers in their work and made a notable impact on the field of cancer immunotherapy. Dr. Schreiber will also give a presentation as a part of this award.

“SITC is proud to continue to bring together the best and brightest minds in cancer immunotherapy to further the science and educate the next generation of scientists and clinicians,” said SITC President Leisha Emens, MD, PhD. “The incredible opportunity for networking with such a diverse audience from so many disciplines really makes this a special event.”

As the largest conference focused solely on cancer immunotherapy, SITC 2023 will feature cutting-edge research presentations by experts in the field, oral and poster abstract presentations and ample opportunity for structured and informal discussions, including important networking opportunities. The meeting also includes updates on major national and international initiatives coming from academia, government and industry.

“We have put together a tremendous line-up of immune-oncology expert speakers presenting the cutting-edge science that is moving our field forward,” said E. John Wherry, PhD, 2023 SITC Annual Program Committee Chair. “It remains a catalytic time for cancer immunology and immunotherapy and the new science and exciting interactions and collaborations that are emblematic of SITC meetings will ultimately help attendees bring novel treatments for patients dealing with cancer.”

You can register now for the SITC’s 38th Annual Meeting & Pre-Conference Programs (SITC 2023), being held from Nov. 1–5, 2023, at the San Diego Convention Center in San Diego, CA. Virtual participation is also available. Visit http://www.sitcancer.org for more information on this event and other SITC resources.

SITC 2023 attendees will:

• Participate in key scientific sessions focused on a variety of basic-, translational- and clinical-focused topics from leaders in the field
• Learn about cutting-edge research via oral abstract presentations and poster presentations – the 37th Annual Meeting had over 1,500 abstract submissions
• Engage with industry representatives and learn about the latest technological advances in our exhibit hall
• Earn continuing education credits
• Connect with other SITC 2023 attendees from around the world

Registration is now underway for SITC 2023, taking place Nov. 1–5, 2023. Click here to register, view sessions, learn about advertising and sponsorship opportunities and more. In addition, SITC is now accepting submissions for Regular and Young Investigator Award Abstracts. The deadline for submissions is June 27, 2023 and can be submitted here.

About SITC

Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.

Share article on social media or email:

“Cancer touches everyone, and it is our team’s belief that people want the most actionable, personalized, and accurate health information possible in the shortest amount of time,” said Mike Mullen, President and CEO of CIRCULOGENE.

BIRMINGHAM, Ala. and PENSACOLA, Fla. (PRWEB)
May 11, 2023

CIRCULOGENE is an innovative medical technology company transforming precision medicine through the rapid delivery of actionable results. Their blood-based, 88-gene panel, used for detecting circulating tumor DNA (ctDNA), was featured in the research study “Analysis of Circulating Tumor DNA for Malignancies Sent at the Time of Endoscopic Visualization: An Optimal Strategy for Diagnosis and Selection of Targeted Therapies.”

Research from the study was presented in Chicago with approximately 800 other abstracts for Digestive Disease Week on Saturday, May 6. The presentation was made by Matthew Grossman, MD, of Atlantic Health System as well as Dawid Nowak, MD; Dhruv Patel, DO; and Devina Adalja, MD, of St. Joseph’s University Medical Center.

The study sent ctDNA on patients with all types of GI malignancy at the time of endoscopic visualization. Results demonstrate how early consideration for ctDNA signatures of cancer can influence first-line chemotherapy and immunotherapy choices.

“This study demonstrates the important role of the gastroenterologist in offering patients superior oncology care,” said Dr. Matthew Grossman, Chief of Gastroenterology at Morristown Medical Center and lead researcher for the study. “Previously, without the use of liquid biopsy, tumor genomics were not considered until the failure of standard chemotherapy. GI doctors have the opportunity to send this test at the time of endoscopy, empowering the oncologist to offer personalized care from day one.”

Advances in genomic sequencing technology have enabled noninvasive detection and molecular profiling of cancers. In this 2-year study, incidence of genetic fragments released by tumors into the bloodstream, known as ctDNA, was evaluated using CIRCULOGENE’s blood-based gene panel to evaluate overall results of ctDNA detection when performed at the time of endoscopy.

In the study, pancreatic, colorectal, gastric, esophageal, and biliary lesions were assessed in 231 patients when doctors determined a high suspicion for malignancy. When ctDNA analysis was sent at the time of endoscopy, the oncologist could use the results to aid decision making for first-line therapy. The study found that ctDNA was positive in 71% of pancreatic cancers and the large majority of other GI malignancies.

“Cancer touches everyone, and it is our team’s belief that people want the most actionable, personalized, and accurate health information possible in the shortest amount of time,” said Mike Mullen, President and CEO of CIRCULOGENE. “Dr. Grossman’s research demonstrates the importance of getting treatment to cancer patients faster which can be done with liquid biopsy testing for DNA, RNA, and MSI all of which CIRCULOGENE provides, in less than a week.”

Dr. Mathew Grossman is the Division Chief of Gastroenterology and Director of Advanced Endoscopy with the Atlantic Medical Group Gastroenterology at Morristown. With clinical interests in therapeutic endoscopy, he has been active in clinical trials of endoscopic devices as well as genomic research on pancreatic duct fluid genomics. Dr. Grossman has written numerous publications in peer-reviewed journals, has presented at many national scientific meetings, and has given frequent talks throughout the GI community about the latest innovations in endoscopy.

About CIRCULOGENE

CIRCULOGENE provides comprehensive biomarker testing for a broad range of cancers allowing physicians to match patient results with specific therapies in just one week. Their sequencing and qPCR methods can provide a full genomic load analysis to help clinicians select targeted therapies, monitor efficacy, and assess recurrence for cancer patients. Applying their liquid biopsy for cfDNA and cfRNA, including PD-L1 and MSI detection, CIRCULOGENE can detect circulating germline and somatic mutations and RNA fusions.

CIRCULOGENE is a Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP) certified laboratory and a Verified Vendor for the federal System for Award Management. For more information, visit our website at circulogene.com, connect with us on LinkedIn, Facebook, and Twitter, email info@circulogene.com, or call us at 855-614-7083. Clinicians interested in ordering tests may also visit our contact page at circulogene.com/contact.

Share article on social media or email: